Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Genzyme Biosurgery (GZBX) was down $0.41 (16%) to $2.10 on 2.3 million shares on Friday after Thursday's post-market news that
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury